Antidepressants, Antipsychotics, Anxiolytics, 2 Volume Set


Book Description

Antidepressants and related psychiatric drugs are the most important prescription drugs worldwide, accounting for a market volume of 20 billion US$ per year. This handbook provides a complete and detailed overview of all currently available psychiatric drugs, covering more than 250 different compounds. Particular features include: * the most important information on the chemistry, pharmacology and therapeutic use of a given drug * a special layout with margin notes and compound structures allowing for quick and easy access to the desired information Written by drug developers from the pharmaceutical industry, novel drugs currently under development and new methods of treatment are listed side by side with classical drugs, allowing a direct comparison of traditional and innovative therapeutic approaches.




Psychiatry, 2 Volume Set


Book Description

Now in a new Fourth Edition, Psychiatry remains the leading reference on all aspects of the current practice and latest developments in psychiatry. From an international team of recognised expert editors and contributors, Psychiatry provides a truly comprehensive overview of the entire field of psychiatry in 132 chapters across two volumes. It includes two new sections, on psychosomatic medicine and collaborative care, and on emergency psychiatry, and compares Diagnostic and Statistical Manual (DSM-5) and International Classification of Diseases (ICD10) classifications for every psychiatric disorder. Psychiatry, Fourth Edition is an essential reference for psychiatrists in clinical practice and clinical research, residents in training, and for all those involved in the treatment psychiatric disorders. Includes a a companion website at www.tasmanpsychiatry.com featuring PDFs of each chapter and downloadable images




Fluoxetine


Book Description

Fluoxetine, best known by the trade name Prozac®, unlike other psychotropic drugs whose effects were serendipitously stumbled upon, was the first developed for a precise mechanism of action, that is, the ability to selectively inhibit serotonin reuptake, based upon the theory that increasing the availability of serotonin would treat major depression. Once approved by the FDA in 1987, fluoxetine quickly became the most prescribed psychotropic drug worldwide and its success in improving mood disorders has triggered the development of a large number of congener molecules, commonly known as SSRIs after their purported mechanism of action. However, a quarter of a century after its development, the idea that fluoxetine asserts its positive behavioral effect through inhibition of serotonergic reuptake is not firmly established. This book reviews several preclinical and clinical reports suggesting that the pharmacological effects of fluoxetine may be mediated by means other than the regulation of serotonin, including the regulation of gene expression, modifying epigenetic mechanisms as well as modifying microRNAs. One of the most prominent mechanisms for the therapeutic relevance of fluoxetine relates to influencing neuroplasticity by enhancing neurotropic factors, including BDNF signaling and altering adult neurogenesis. The ability of fluoxetine to rapidly increase neurosteroid levels accounts for the fast anxiolytic effects of this drug. Fluoxetine action at sigma-1 receptor or modulating glutamatergic neurotransmission as well as the combination of fluoxetine with other psychotropic drugs is discussed in relation to its therapeutic effects. While fluoxetine was primarily prescribed as an antidepressant, this drug currently represents a treatment of choice for a broad spectrum of psychiatric disorders, including post-traumatic stress disorder and a range of anxiety disorders. This drug even possesses analgesic actions and is a valuable therapy for stroke. This book also highlights emerging evidence on the gender-specific effects of fluoxetine, its potential adverse features, including its addiction liability in combination with psychostimulants, and the impact of perinatal fluoxetine exposure.




Drug-Induced Liver Injury


Book Description

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series




The American Psychiatric Association Publishing Textbook of Psychopharmacology


Book Description

The American Psychiatric Association Publishing Textbook of Psychopharmacology is an indispensable and comprehensive resource for clinicians and trainees who prescribe psychotropic medications. Updated to reflect the new DSM-5 classification, this revised Fifth Edition maintains the user-friendly structure of its predecessors while offering in-depth coverage of the latest research in pharmacological principles, classes of drugs, and psychiatric disorders. Introductory chapters provide a theoretical grounding in clinical applications, with topics ranging from neurotransmitters to brain imaging in psychopharmacology. The bulk of the book is devoted to various classes of drugs, including antidepressants, anxiolytics, antipsychotics, mood stabilizers, and other agents, with each class divided into chapters on specific drugs -- either new or revised to include the latest findings and trends. Finally, the section on psychopharmacological treatment addresses evidence-based principles of clinical care for the full spectrum of mental disorders and conditions -- from depression to chronic pain -- as well as for specific populations and circumstances -- from children and adolescents to psychiatric emergencies -- offering information on topics such as medication selection, combination and maintenance dosing regimens, monitoring and management of side effects, and strategies for optimizing treatment response. The book's beneficial features are many: The section on principles of pharmacology has been revised and reorganized to incorporate recent discoveries from the fields of neurobiology, genetics, brain imaging, and epidemiology. History and discovery, structure--activity relationships, pharmacological profiles, pharmacokinetics and disposition, mechanisms of action, indications and efficacy, side effects and toxicology, and drug--drug interactions are addressed for each agent. This consistent structure places the desired information at the clinician's fingertips and facilitates study for trainees. Coverage of drugs approved since the last edition is thorough, encompassing new antidepressants (e.g., vortioxetine), new antipsychotics (e.g., cariprazine), and agents on the clinical horizon (e.g., ketamine). More than 180 tables and graphs present critically important data in an accessible way. A work of uncommon scientific rigor and clinical utility, The American Psychiatric Association Publishing Textbook of Psychopharmacology provides state-of-the-art information on both the principles and the practice of psychopharmacological treatment of psychiatric disorders.




The Neuropsychology of Psychopathology


Book Description

Print+CourseSmart




Happy Pills in America


Book Description

Valium. Paxil. Prozac. Prescribed by the millions each year, these medications have been hailed as wonder drugs and vilified as numbing and addictive crutches. Where did this “blockbuster drug” phenomenon come from? What factors led to the mass acceptance of tranquilizers and antidepressants? And how has their widespread use affected American culture? David Herzberg addresses these questions by tracing the rise of psychiatric medicines, from Miltown in the 1950s to Valium in the 1970s to Prozac in the 1990s. The result is more than a story of doctors and patients. From bare-knuckled marketing campaigns to political activism by feminists and antidrug warriors, the fate of psychopharmacology has been intimately wrapped up in the broader currents of modern American history. Beginning with the emergence of a medical marketplace for psychoactive drugs in the postwar consumer culture, Herzberg traces how “happy pills” became embroiled in Cold War gender battles and the explosive politics of the “war against drugs”—and how feminists brought the two issues together in a dramatic campaign against Valium addiction in the 1970s. A final look at antidepressants shows that even the Prozac phenomenon owed as much to commerce and culture as to scientific wizardry. With a barrage of “ask your doctor about” advertisements competing for attention with shocking news of drug company malfeasance, Happy Pills is an invaluable look at how the commercialization of medicine has transformed American culture since the end of World War II.




Pharmacology of Intestinal Permeation II


Book Description

The intestine, particularly the small bowel, represents a large surface (in the adult 2 human approximately 200 m ) through which the body is exposed to its environ ment. A vigorous substrate exchange takes place across this large surface: nutrients and xenobiotics are absorbed from the lumen into the bloodstream or the lymph, and simultaneously, the same types of substrate pass back into the lumen. The luminal surface of the intestine is lined with a "leaky" epithelium, thus the passage of the substrates, in either direction, proceeds via both transcellular and intercellular routes. Simple and carrier-mediated diffusion, active transport, pinocytosis, phagocytosis and persorption are all involved in this passage across the intestinal wall. The term "intestinal permeation" refers to the process of passage of various substances across the gut wall, either from the lumen into the blood or lymph, or in the opposite direction. "Permeability" is the condition of the gut which governs the rate of this complex two-way passage. The pharmacologist's interest in the problem of intestinal permeation is twofold: on the one hand, this process determines the bioavailability of drugs and contributes significantly to the pharmacokinetics and toxicokinetics of xeno biotics; on the other hand, the pharmacodynamic effects of many drugs are manifested in a signigicant alteration of the physiological process of intestinal permeation.




Radiocontrast Agents


Book Description

Contrast media are drugs by default. Had there been no default, there would be no need for a related pharmacology, and thus no need for this book. Radiographic contrast media (CM) are substances whose primary purpose is to enhance diagnostic information of medical imaging systems. The position of CM in pharmacology is unique. First, there is the unusual requirement of biological inertness. An ideal CM should be completely biologically inert, i.e., stable, not pharmacologically active, and efficiently and innocuously excretable. Because they fail to meet these requirements, CM must be considered drugs. The second unusual aspect of CM is that they are used in large quantities, their annual production being measured in tens of tons. It is not in spite of, but because of, the increased use of new radiographic systems, computed tomography, digital radiography, etc., that consumption is on the rise. And, it is not likely that the other emerging imaging modalities - NMR, ultrasonography, etc. - will displace radiographic CM soon; it is quite probable that these remarkable compounds will continue to play an active role in diagnostic imaging in the foreseeable future.




Dermatology - E-Book


Book Description

**Selected for Doody's Core Titles® 2024 in Dermatology**For dermatology residents and trainees, as well as those in clinical practice, Dermatology is the leading reference for understanding, diagnosing, and treating the full spectrum of skin disease—and is the key resource that residents rely on throughout their training and certification. Widely recognized for its easy-in, easy-out approach, this revised 5th Edition turns complex information into user-friendly visual content through the use of clear, templated chapters, digestible artwork, and easy-to-follow algorithms and tables. This two-volume masterwork provides complete, authoritative coverage of basic science, clinical practice of both adult and pediatric dermatology, dermatopathology, and dermatologic surgery—more than any other source, making it the gold standard reference in the field today. - Simplifies complex content in a highly accessible, highly visual manner, with 1,100+ tables; 2,600+ figures, including numerous disease classification algorithms as well as diagnostic and therapeutic pathways; and over 1,500 additional figures and tables online. - Utilizes weighted differential diagnosis tables and a "ladder" approach to therapeutic interventions. - Any additional digital ancillary content may publish up to 6 weeks following the publication date. - Features an intuitive organization and color-coded sections that allow for easy and rapid access to the information you need. - Retains an emphasis on clinicopathologic correlations, with photomicrographs demonstrating key histologic findings adjacent to clinical images of the same disorder. - Contains updated treatment information throughout, including immune checkpoint inhibitors, JAK inhibitors, and monoclonal antibodies for a wide range of conditions such as psoriasis, atopic dermatitis, alopecia areata, vitiligo, and skin cancers. - Provides up-to-date information on genetic and molecular markers and next-generation sequencing as it applies to dermatologists. - Features new videos, including cryosurgical and suturing techniques, treatment of rhinophyma via electrosection, and neuromodulator treatment of axillary hyperhidrosis. - Includes new WHO classifications of skin tumors, new FDA pregnancy drug labeling, and new ACR/EULAR criteria for vasculitis and lupus erythematosus. - Includes new sections on confocal microscopy and artificial intelligence.